MedTrace Logo

First in Man Study With SLV341

NCT00887445 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2010-04-28

No results posted yet for this study

Summary

First in man study with single and multiple rising doses with SLV341

Conditions

Interventions

DRUG

SLV341

5 - 1000mg once daily

DRUG

placebo

Sponsors & Collaborators

  • Quintiles, Inc.

    collaborator INDUSTRY

  • Solvay Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Ingrid Meuwsen · Solvay Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00887445 on ClinicalTrials.gov